Trends in prevalence and treatment of ocular allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 5, 2014, Pages 451-456

  Gomes, Paulo J ^a  

^a Ora Inc   (United States)

Author keywords

allergic conjunctivitis; rhinoconjunctivitis; sublingual immunotherapy

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID;

EYE ALLERGY; HUMAN; IMMUNOTHERAPY; MORBIDITY; PERENNIAL ALLERGIC CONJUNCTIVITIS; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; TREATMENT RESPONSE; CONJUNCTIVITIS, ALLERGIC; PROCEDURES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TOPICAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CONJUNCTIVITIS, ALLERGIC; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOTHERAPY; PREVALENCE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; UNITED STATES;

EID: 84906936502     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000100     Document Type: Review

References (49)

1. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005; 115:118-122.
2. Miraldi V, Kaufman AR. Allergic eye disease. Pediatr Clin North Am 2014; 61:607-620.
3. O'Brien TP. Allergic conjunctivitis: an update on diagnosis and management. Curr Opin Allergy Clin Immunol 2013; 13:543-549.
4. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011; 11:471-476.
5. Virchow JC, Kay S, Demoly P, et al. Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients: an observational, cross sectional study in four countries in Europe. J Med Econ 2011; 14:305-314.
6. Mullol J, Bartra J, del Cuvillo A, et al. Specialist-based treatment reduces the severity of allergic rhinitis. Clin Exp Allergy 2013; 43:723-729.
7. Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: a review. J Am Acad Dermatol 2014; 70:569-575.
8. De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol 2013; 97:9-14.
9. Leonardi A. Allergy and allergic mediators in tears. Exp Eye Res 2013; 117:106-117.
10. Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep 2011; 11:205-211.
11. Emre S, Başer E, Oztürk B, et al. Corneal biochemical features of patients with vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2013; 251:555-558.
12. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-743.
13. Ait-Khaled N, Pearce N, Anderson HR, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009; 64:123-148.
14. Mallol J, Crane J, von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr) 2013; 41:73-85.
15. Banac S, Rožmanić V, Manestar K, et al. Rising trends in the prevalence of asthma and allergic diseases among school children in the north-west coastal part of Croatia. J Asthma 2013; 50:810-814.
16. Chong Neto HJ, Rosário CS, Rosário BA, et al. Allergic rhinitis in preschool children from Southern Brazil. Allergy 2014; 69:545-547.
17. Levin ME, Muloiwa R, Motala C. Associations between asthma and bronchial hyper-responsiveness with allergy and atopy phenotypes in urban black South African teenagers. S Afr Med J 2011; 101:472-476.
18. Maspero J, Lee BW, Katelaris CH, et al. Quality of life and control of allergic rhinitis in patients from regions beyond Western Europe and the United States. Clin Exp Allergy 2012; 42:1684-1696.
19. Hom MM, Bielory L. The anatomical and functional relationship between allergic conjunctivitis and allergic rhinitis. Allergy Rhinol (Providence) 2013; 4:e110-e119.
20. Williams DC, Edney G, Maiden B, Smith PK. Recognition of allergic conjunctivitis in patients with allergic rhinitis. World Allergy Organ J 2013; 6:4.
21. Guarnieri M, Balmes JR. Outdoor air pollution and asthma. Lancet 2014; 383:1581-1592.
22. Fujishima H, Satake Y, Okada N, et al. Effects of diesel exhaust particles on primary cultured healthy human conjunctival epithelium. Ann Allergy Asthma Immunol 2013; 110:39-43.
23. Wang P, Thevenot P, Saravia J, et al. Radical-containing particles activate dendritic cells and enhance Th17 inflammation in a mouse model of asthma. Am J Respir Cell Mol Biol 2011; 45:977-983.
24. van Voorhis M, Knopp S, Julliard W, et al. Exposure to atmospheric particulate matter enhances Th17 polarization through the aryl hydrocarbon receptor. PLoS One 2013; 8:e82545.
25. Brandt EB, Kovacic MB, Lee GB, et al. Diesel exhaust particle induction of IL-17A contributes to severe asthma. J Allergy Clin Immunol 2013; 132:1194-1204.
26. Brauer M, Amann M, Burnett RT, et al. Exposure assessment for estimation of the global burden of disease attributable to outdoor air pollution. Environ Sci Technol 2012; 46:652-660.
27. Ackerman S, D'Ambrosio F Jr, Greiner JV, et al. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy 2013; 6:43-52.
28. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract 2014; 2:332-340.
29. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nature Med 2012; 18:736-749.
30. Al-Amri AM. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol 2014; 157:280-286.
31. Oray M, Toker E. Tear cytokine levels in vernal keratoconjunctivitis: the effect of topical 0.05% cyclosporine a therapy. Cornea 2013; 32:1149-1154.
32. Fukushima A, Ohashi Y, Ebihara N, et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol 2014; 98:1023-27.
33. Ueta M, Sotozono C, Koga A, et al. Usefulness of a new therapy using rebamipide eyedrops in patients with VKC/AKC refractory to conventional antiallergic treatments. Allergol Int 2014; 63:75-81.
34. Hom MM, Nguyen AL, Bielory L. Allergic conjunctivitis and dry eye syndrome. Ann Allergy Asthma Immunol 2012; 108:163-166.
35. Gomes PJ, Ousler GW, Welch DL, et al. Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy. Clin Ophthalmol 2013; 7:157-165.
36. Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy 2012; 2:2.
37. Frati F, Incorvaia C, Passalacqua G. Efficacy of sublingual immunotherapy. J Am Med Assoc 2013; 310:643-644.
38. Nelson HS. Is sublingual immunotherapy ready for use in the United States? J Am Med Assoc 2013; 309:1297-1298.
39. Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immuno-therapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014; 112:146-153.
40. Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013; 131:1342-1349.
41. Didier A, Malling HJ, Worm M, et al. Posttreatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013; 43:568-577.
42. Aydogan M, Eifan AO, Keles S, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomized trial. Respir Med 2013; 107:1322-1329.
43. Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract 2014; 2:144-149.
44. Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy 2011; 41:1263-1272.
45. Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 2013; 131:1155-1167.
46. Makatsori M, Pfaar O, Calderon MA. Allergen immunotherapy: clinical outcomes assessment. J Allergy Clin Immunol Pract 2014; 2:123-129.
47. Abelson MB. Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999; (228):38-42.
48. Sager A, Worm M. Allergen immunotherapy dose optimizing study of a depigmented polymerized allergen extract of birch pollen by means of conjunctival provocation test. World Allergy Organiz J 2012; 5 (Suppl 2):S18.
49. Dreborg S, Lee TH, Kay AB, Durham SR. Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients. Int Arch Allergy Immunol 2012; 158:63-70.